Is there still a role for edrophonium in diagnosing ocular myasthenia.
Karatas
H
H
Nurlu
G
G
Kansu
T
T
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D001763:Blepharoptosis / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D002800:Cholinesterase Inhibitors; D003937:Diagnosis, Differential; D004491:Edrophonium; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000175:diagnosis* / Q000503:physiopathology; D015835:Ocular Motility Disorders / Q000175:diagnosis / Q000209:etiology / Q000503:physiopathology; D009801:Oculomotor Muscles / Q000187:drug effects* / Q000294:innervation / Q000503:physiopathology*; D011237:Predictive Value of Tests; D011729:Pyridostigmine Bromide / Q000627:therapeutic use; D011978:Receptors, Nicotinic / Q000187:drug effects / Q000276:immunology
D000305:Adrenal Cortex Hormones; D002800:Cholinesterase Inhibitors; D011978:Receptors, Nicotinic; D004491:Edrophonium; D011729:Pyridostigmine Bromide